Newtag icon
Top Black Friday 2025 brands announced! What were the hottest products and categories?Download the report now 👉banner icon
Sorrento Therapeutics

November 2025

  • Home
  • Sorrento Therapeutics

Sorrento Therapeutics Market Share Analysis for November 2025

COOKIE POLICY This Cookie Policy describes how explains how Sorrento Therapeutics, Inc. and its affiliates and subsidiaries (collectively, “Sorrento,” “us,” “we,” or “our”) use cookies and similar technologies in connection with the websites, applications, and portals we operate that link to this Cookie Policy (collectively, the “Site”) to provide, improve, promote, and protect the Site […]
Year Founded1989
Employees501 - 1000
Annual Revenue$50M - $75M
levenabiopharma.com
sorrentotherapeutics.com
Sorrento Therapeutics
Showing Sorrento Therapeutics's traffic and engagement information for its main website (including company regionals)
  • sorrentotherapeutics.com
    sorrentotherapeutics.com
  • levenabiopharma.com
    levenabiopharma.com
See more website traffic and engagement information

Sorrento Therapeutics Revenue up to November 2025 is 50M - 75M

revenue generated by Sorrento Therapeutics top domains

Sorrento Therapeutics top domains revenue over 3 years

Revenue for Sorrento Therapeutics top domains

sorrentotherapeutics.comsorrentotherapeutics.com50M - 75M
levenabiopharma.comlevenabiopharma.com5M - 10M
See more with Sales Intelligence

Total visits to Sorrento Therapeutics's top domains

Understand Sorrento Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown
sorrentotherapeutics.comsorrentotherapeutics.com710
levenabiopharma.comlevenabiopharma.com288
See more with Sales Intelligence

Avg. visit duration in Sorrento Therapeutics's top domains

Analyze Sorrento Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown
sorrentotherapeutics.comsorrentotherapeutics.com00:01:11
levenabiopharma.comlevenabiopharma.com00:01:14
See more with Sales Intelligence

Avg. pageviews on Sorrento Therapeutics's top domains

See how Sorrento Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown
sorrentotherapeutics.comsorrentotherapeutics.com2.17
levenabiopharma.comlevenabiopharma.com2.40
See more with Sales Intelligence

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.


Sorrento Therapeutics top competitors by domain

Top similar sites in November 2025, ranked by their affinity

Benchmark Your Digital Performance

Identify high-value opportunities, track your performance, and win your market.


Top technologies used by Sorrento Therapeutics

These are the website technologies, by industry, used by Sorrento Therapeutics top domains

Widget (3)

Twemoji

Twemoji

Advertising (2)

DoubleClick

DoubleClick

Content Management System (2)

WordPress

WordPress

Conversion & Analytics (2)

Google Analytics

Google Analytics

More Technologies

7

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from Sorrento Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSorrento Therapeutics, Inc. has issues with securities fraud suit.The U.S. Court of Appeals for the Ninth Circuit dismissed a securities fraud suit against biopharmaceutical company Sorrento Therapeutics, concluding its claims that it found a "cure" for COVID-19, which led to a spike in stock prices, wasn't materially false or misleading.
NewsSorrento Therapeutics, Inc. launched Offering to Dividend Short Holders on Jul 27th '23.Sorrento announces launch of voluntary Offering to Dividend Short Holders with deadline to participate by July 27, 2023.
NewsSorrento Therapeutics, Inc. launches positive findings from a phase IIa study conducted in China on Abivertinib.Sorrento Therapeutics, Inc. (OTC: SRNEQ) has released positive findings from a phase IIa study conducted in China on Abivertinib, a dual inhibitor targeting mutant EGFR and BTK.

See all Sorrento Therapeutics signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.